Mar 27, 2025

Featuring an interview with Dr Sara A Hurvitz, including the following topics:

• Role of endocrine therapy in the management of HER2-positive breast cancer; implications of the Phase III PATINA study (0:00)
• Case: A woman in her mid 60s with node-negative, HR-positive, HER2-negative localized breast cancer and a Recurrence Score^® of 28 (8:38)
• Available data guiding the selection of an adjuvant CDK4/6 inhibitor (12:49)
• Selection of a CDK4/6 inhibitor in the metastatic setting (23:16)
• Available therapies for patients with HR-positive metastatic breast cancer (mBC) and PIK3CA mutations; implications of the Phase III INAVO120 study (29:17)
• Case: A woman in her early 60s with HR-positive, HER2-negative mBC with short duration of benefit from a first-line CDK4/6 inhibitor and an aromatase inhibitor (AI) and coexisting PIK3CA and ESR1 mutations (37:11)
• Available data with approved and investigational oral SERDs (selective estrogen receptor degraders) (43:23)
• Case: A woman in her early 70s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after durable responses to first-line endocrine therapy and second-line CDK4/6 inhibitor with an AI (51:38)
• Selection of therapy for patients with HR-positive mBC and coexisting targetable genetic mutations (53:11)
• Case: A woman in her late 50s with HR-positive, HER2-negative mBC and an ESR1 mutation detected on disease progression after first-line CDK4/6 inhibitor with an AI (1:00:17)

CME information and select publications